<DOC>
	<DOC>NCT00055562</DOC>
	<brief_summary>Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.</brief_summary>
	<brief_title>Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand and voluntarily sign an informed consent form. Able to adhere to the study visit schedule and other protocol requirements. Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug. Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Metastatic Malignant Melanoma</keyword>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
</DOC>